Rollins Inc.
ROL
$34.82
-1.39%
Rollins, Inc. is a global leader in route-based pest control services, operating primarily through its flagship Orkin brand across the United States, Canada, and a growing international footprint spanning Europe, the Middle East, Africa, Australia, and Latin America. The company's portfolio of brands delivers recurring residential and commercial pest control, termite prevention, and ancillary services, giving it a subscription-like revenue model with high customer retention and predictable cash generation characteristic of a best-in-class specialty business services operator. The current investor narrative is dominated by a sharp deterioration in sentiment: despite mid-single-digit organic revenue growth and steady margin execution, the stock has de-rated dramatically as investors question whether the premium multiple historically afforded to this defensive compounder is sustainable in a higher-rate, slower-growth environment. Recent analyst actions — including downgrades to Neutral and Hold from Piper Sandler and Argus Research — alongside a broad-based compression in valuation multiples, frame the debate around whether Rollins' durable route-density economics and acquisition-driven consolidation strategy can re-accelerate growth enough to justify its still-elevated earnings multiple.…
ROL
Rollins Inc.
$34.82
People also watch
Cintas
CTAS
Copart
CPRT
Ritchie Bros. Auctioneers
RBA
Aramark
ARMK
UL Solutions Inc.
ULS
Investment Opinion: Should I buy ROL Today?
The synthesized recommendation is Hold. Rollins is a high-quality, cash-generative business with a durable route-based model, but the current valuation (55.06x trailing PE, 28.17x forward PE) and negative momentum (-38.69% over one year) warrant caution. The analyst consensus is 'hold' with a mean rating of 2.58 and an average target of $37.24, implying only +6.9% upside from $34.82.
Supporting evidence includes revenue growth of 7.91% year-over-year in Q2 2026, robust free cash flow of $619.2 million (2.13% FCF yield), and exceptional ROE of 38.32%. However, margins are compressing—gross margin fell to 49.73% from 53.79%, and operating margin declined to 18.67% from 19.84%. The PEG ratio of 4.07x and EV/EBITDA of 35.12x suggest the stock remains expensive relative to its growth rate, even after the significant de-rating.
The biggest risks are further margin deterioration, a breakdown below the 52-week low of $29.29, and continued analyst downgrades. The rating would upgrade to Buy if the stock stabilizes above the $38–$40 resistance zone and margins show signs of troughing, or if forward PE compresses below 25x. It would downgrade to Sell if revenue growth decelerates below 5% or if the stock breaks below $29.29. Relative to its history, the PS ratio of 7.73x is near the low end of its 18x–32x range, suggesting value is emerging on a revenue basis, but earnings-based valuation remains stretched.
Sign up to view all
ROL 12-Month Price Forecast
Rollins is a high-quality defensive compounder undergoing a painful de-rating as the market reprices its premium multiple for a slower-growth, higher-rate environment. The business remains fundamentally sound with robust free cash flow and exceptional returns on capital, but margin compression and negative analyst momentum suggest the near-term path of least resistance is sideways to lower. The stock's deeply oversold position near the 52-week low and nascent 1-month relative strength (+8.19% vs. SPY) hint at a potential bounce, but confirmation of a trend reversal is lacking. I would upgrade to bullish if margins stabilize and the stock reclaims the $38–$40 resistance zone, and downgrade to bearish if it breaks below $29.29 or if revenue growth falls below 6%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rollins Inc.'s 12-month outlook, with a consensus price target around $37.24 and implied upside of +6.9% versus the current price.
Average Target
$37.24
0 analysts
Implied Upside
+6.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $46
Analyst target range
Coverage is broad with 17 analysts, but sentiment is decidedly cautious: the consensus recommendation is "hold" with a mean rating of 2.58 (where 1 is strong buy and 5 is strong sell), and the average target price of $37.24 implies roughly +6.9% upside from the current $34.82. This is a lukewarm consensus — not bearish enough to signal capitulation, but far from the bullish conviction that typically accompanies a premium-multiple compounder. The distribution of recent institutional ratings confirms the neutral-to-cautious tilt, with BNP Paribas, Wells Fargo, UBS, Canaccord, and Piper Sandler all at Neutral/Hold/Underweight, while only Morgan Stanley and Barclays maintain Overweight.
The target range of $26.00 to $46.00 is wide — a spread of roughly 77% between low and high — signaling meaningful disagreement about the company's trajectory. The high target of $46.00 (about +32% upside) likely assumes multiple stabilization, re-acceleration of organic growth, and successful acquisition integration, while the low target of $26.00 (about -25% downside) prices in continued margin compression, competitive pressure, or a prolonged de-rating. Notably, recent rating actions have skewed negative — Piper Sandler downgraded from Overweight to Neutral on September 24 and Argus moved from Buy to Hold on August 5 — suggesting analysts are trimming expectations rather than upgrading, which reinforces the cautious stance and implies the burden of proof remains on upcoming earnings to reverse the negative momentum.
Drowning in data?
Find the real signal!
Bulls vs Bears: ROL Investment Factors
The bear case currently has stronger evidence: ROL remains expensive on both trailing (55.06x PE) and forward (28.17x PE) bases relative to its sub-8% revenue growth, margins are compressing, and analyst sentiment has turned negative with recent downgrades. However, the bull case is not without merit—the stock is deeply oversold near its 52-week low, free cash flow remains robust at $619.2 million, and the 1-month relative strength of +8.19% versus SPY hints at a potential mean-reversion bounce. The single most important tension is whether Rollins' premium multiple can be justified by re-accelerating organic growth and margin stabilization, or whether the de-rating has further to run as the market reprices a defensive compounder for a higher-rate, slower-growth world. Resolution likely hinges on the next few earnings reports showing whether margin compression is transitory or structural.
Bullish
- Deeply oversold near 52-week low: At $34.82, ROL trades at just 14.6% of its 52-week range ($29.29–$66.14) after a -38.69% one-year decline and a -54.74% max drawdown. The 1-month change of +7.17% versus SPY's -1.02% (relative strength +8.19%) suggests a mean-reversion bounce is underway from deeply oversold levels.
- Strong FCF and capital efficiency: Trailing free cash flow of $619.2 million against a $29.06 billion market cap yields roughly 2.13%, while ROE of 38.32% and ROA of 13.93% reflect exceptional capital efficiency. Q2 2026 operating cash flow of $172.5 million versus capex of just $6.4 million underscores the asset-light, cash-generative nature of the route-based model.
- Recurring revenue with steady growth: Q2 2026 revenue of $1.079 billion grew 7.91% year-over-year, driven by residential pest control at $485.8 million, commercial at $347.9 million, and termite/ancillary at $234.2 million. The subscription-like route density model supports high customer retention and predictable cash generation.
- Analyst target implies upside: The average analyst target of $37.24 implies +6.9% upside from $34.82, with a high target of $46.00 (+32%). While the consensus is 'hold' (mean 2.58), the wide $26–$46 range signals meaningful disagreement and potential for re-rating if execution improves.
Bearish
- Premium valuation despite de-rating: Trailing PE of 55.06x and forward PE of 28.17x remain well above the specialty business services sector average in the low-to-mid 20s. The PEG ratio of 4.07x and EV/EBITDA of 35.12x are elevated for a business growing revenue at under 8%, leaving little room for error.
- Margin compression evident: Q2 2026 gross margin of 49.73% fell from 53.79% a year earlier, and operating margin declined to 18.67% from 19.84%. Net margin also slipped to 13.34% from 14.16%, reflecting cost pressure or mix shift that threatens the premium multiple thesis.
- Negative analyst momentum: Piper Sandler downgraded from Overweight to Neutral on September 24, and Argus moved from Buy to Hold on August 5. The consensus 'hold' rating (mean 2.58) with only Morgan Stanley and Barclays at Overweight signals cautious sentiment and a burden of proof on upcoming earnings.
- Tight liquidity and debt-funded M&A: The current ratio of 0.60 signals tight short-term liquidity, while debt-to-equity of 0.755 is notable given the acquisition-driven strategy. Q2 2026 saw $116.8 million in acquisitions and $52.0 million in debt repayment, raising integration and leverage risk.
ROL Technical Analysis
Rollins is in a pronounced, sustained downtrend, with the 1-year price change of -38.69% and a year-to-date decline of -40.99% placing it deep in bear-market territory and dramatically underperforming the S&P 500's +13.13% over the same period (relative strength of -51.82%). At the current price of $34.82, the stock sits at roughly 14.6% of its 52-week range (low of $29.29, high of $66.14), meaning it is trading near the very bottom of its annual band — a positioning that historically signals either capitulation/value opportunity or a falling knife, and the persistent lower highs throughout 2026 argue caution until a base forms. The max drawdown of -54.74% underscores the severity of the de-rating from peak levels.
Short-term momentum, however, shows a nascent divergence from the longer-term trend: the 1-month change of +7.17% contrasts sharply with the -9.70% 3-month and -38.48% 6-month declines, and the relative strength versus SPY over the past month is a strong +8.19% (against SPY's -1.02%). This suggests the stock may be attempting a mean-reversion bounce off deeply oversold levels near the $29.29 low, with the recent move from $29.69 (October 5) to $35.31 (October 22) representing roughly a 19% off-bottom rally. That said, the bounce remains unconfirmed against a still-intact primary downtrend, and volume of 9.09 million shares on the latest session indicates active repositioning rather than conviction accumulation.
Key technical levels are well defined: support rests at the 52-week low of $29.29, and a breakdown below that level would signal a continuation of the bear trend and likely trigger further momentum-driven selling. Resistance sits at the 52-week high of $66.14, but more immediately relevant is the $38-$40 zone where the July breakdown accelerated — reclaiming that area would be the first meaningful sign of trend repair. With a beta of 0.731, Rollins is roughly 27% less volatile than the broad market, which historically supports defensive positioning and smaller position-sizing adjustments, though the stock's own idiosyncratic drawdown of -54.74% demonstrates that low beta has not insulated shareholders from severe multiple compression.
Beta
0.73
0.73x market volatility
Max Drawdown
-54.7%
Largest decline past year
52-Week Range
$29-$66
Price range past year
Annual Return
-38.7%
Cumulative gain past year
| Period | ROL Return | S&P 500 |
|---|---|---|
| 1m | +7.2% | -1.5% |
| 3m | -9.7% | +2.8% |
| 6m | -38.5% | +6.8% |
| 1y | -38.7% | +12.2% |
| ytd | -41.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ROL Fundamental Analysis
Revenue growth remains intact but is decelerating in absolute terms: Q2 2026 revenue of $1.079 billion grew 7.91% year-over-year versus $999.5 million in Q2 2025, a solid but unspectacular pace for a defensive compounder. Sequentially, revenue rose from $906.4 million in Q1 2026 to $1.079 billion in Q2, reflecting normal seasonality, while the prior-year comparison shows Q2 2025's $999.5 million was up from Q1 2025's $822.5 million. Segment data reveals the growth engine is residential pest control at $485.8 million, followed by commercial at $347.9 million and termite/ancillary at $234.2 million, with franchise and other contributing a combined ~$10.2 million — a diversified mix that supports recurring revenue but offers limited upside surprise potential.
Profitability is robust and improving: Q2 2026 net income of $143.9 million on a 13.34% net margin compares favorably to Q2 2025's $141.5 million at a 14.16% margin, while gross margin of 49.73% in Q2 2026 was slightly below the 53.79% reported in Q2 2025, reflecting cost pressure or mix shift. Operating income of $201.4 million (18.67% operating margin) in Q2 2026 versus $198.3 million (19.84%) a year earlier shows modest margin compression, and the trailing gross margin of 52.75% and operating margin of 19.30% remain healthy for the specialty services industry. The company is solidly profitable with a 14.00% net margin, and the sequential progression from Q1 2026's 11.90% net margin to Q2's 13.34% demonstrates the seasonal earnings leverage inherent in the route-based model.
Balance sheet and cash generation are the strongest part of the story: trailing free cash flow of $619.2 million against a $29.06 billion market cap implies an FCF yield of roughly 2.13%, while ROE of 38.32% and ROA of 13.93% reflect exceptional capital efficiency. However, the current ratio of 0.60 signals tight short-term liquidity, and debt-to-equity of 0.755 is moderate but notable given the company's acquisition-driven strategy — Q2 2026 alone saw $116.8 million in acquisitions and $52.0 million in debt repayment. The company funds growth internally (Q2 operating cash flow of $172.5 million versus capex of just $6.4 million) and returns capital via $88.1 million in dividends and $20.5 million in buybacks, but the low current ratio and reliance on debt for M&A warrant monitoring.
Quarterly Revenue
$1.1B
2026-06
Revenue YoY Growth
+7.9%
YoY Comparison
Gross Margin
49.7%
Latest Quarter
Free Cash Flow
$619169000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ROL Overvalued?
Because Rollins is solidly profitable (Q2 2026 net income of $143.9 million), the PE ratio is the appropriate primary metric. The trailing PE of 55.06x against a forward PE of 28.17x implies the market expects earnings to roughly double — a gap that reflects both the depressed trailing earnings base and optimistic forward estimates of $1.597 in average EPS. The PEG ratio of 4.07x, however, signals that even on forward numbers the stock is expensive relative to its growth rate, and the EV/EBITDA of 35.12x is elevated for a business growing revenue at under 8%.
Against the specialty business services industry, Rollins trades at a significant premium: its PS ratio of 7.73x and EV/Sales of 4.49x sit well above typical sector levels, while the 55x trailing PE versus a sector average in the low-to-mid 20s represents a premium of well over 100%. This premium has historically been justified by Rollins' superior margins (52.75% gross, 19.30% operating), recurring revenue model, and consolidation opportunity — but with growth decelerating to 7.91% and the stock down 38.69% over the year, the market is clearly questioning whether that premium is still warranted. The 21.14x price-to-book ratio is extreme and reflects the asset-light, high-ROE nature of the business rather than tangible book value.
Historically, Rollins' PE has ranged from roughly 34.8x (Q2 2026) to 65.8x (Q4 2021), with the current 55.06x trailing multiple sitting in the upper-middle of that band — but critically, the historical ratios show the PE was 34.78x as recently as the Q2 2026 report, meaning the multiple has expanded even as the price collapsed, because earnings fell faster than the stock. The PS ratio of 7.73x is near the low end of its historical 18x-32x range, suggesting the price decline has compressed the sales multiple dramatically, which could indicate value emerging on a revenue basis even as earnings-based valuation remains stretched.
PE
55.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin compression and liquidity. Q2 2026 gross margin fell to 49.73% from 53.79% a year earlier, and operating margin declined to 18.67% from 19.84%, while net margin slipped to 13.34% from 14.16%. The current ratio of 0.60 signals tight short-term liquidity, and debt-to-equity of 0.755 is notable given the acquisition-driven strategy—Q2 2026 alone saw $116.8 million in acquisitions and $52.0 million in debt repayment. Revenue concentration in residential pest control ($485.8 million of $1.079 billion) and reliance on continued growth to justify the premium multiple add to the risk profile.
Market and competitive risks include valuation compression and sector rotation. At 55.06x trailing PE and 35.12x EV/EBITDA, ROL trades at a significant premium to the specialty business services sector, leaving it vulnerable to further multiple contraction if growth decelerates. Beta of 0.731 offers some insulation from broad market swings, but the stock's own -54.74% max drawdown demonstrates that low beta has not protected against idiosyncratic de-rating. Recent downgrades from Piper Sandler and Argus, along with a consensus 'hold' rating, reflect emerging skepticism that could pressure the shares further.
The worst-case scenario involves a continuation of the downtrend, with the stock breaking below the 52-week low of $29.29 and testing the analyst low target of $26.00. From the current $34.82, that represents a decline of approximately -25.3%, and a drop to the 52-week low would be -15.9%. Such a move could be triggered by a miss on Q3 earnings, further margin deterioration, or a broader market rotation away from defensive compounders. The max drawdown of -54.74% from peak illustrates the severity of what a full de-rating could look like.
FAQ
The most severe risk is continued margin compression—gross margin fell to 49.73% in Q2 2026 from 53.79% a year earlier, and operating margin declined to 18.67% from 19.84%. Second, valuation risk remains high: at 55.06x trailing PE and 35.12x EV/EBITDA, further multiple contraction could drive the stock toward the analyst low target of $26.00. Third, liquidity risk is notable with a current ratio of 0.60 and debt-to-equity of 0.755, especially given the acquisition-driven strategy. Fourth, technical risk: the stock is in a pronounced downtrend, and a break below the 52-week low of $29.29 could trigger momentum-driven selling. These risks are ranked in order of severity, with margin compression being the most immediate threat to the investment thesis.
The 12-month forecast is balanced with a neutral stance. The base case (50% probability) targets $35–$39, assuming revenue growth holds at 7-8% and gross margin stabilizes around 50-52%. The bull case (25% probability) targets $42–$46, driven by margin recovery and analyst upgrades. The bear case (25% probability) targets $26–$29, reflecting continued margin compression and a breakdown below the 52-week low. The most likely scenario is the base case, with the key assumption being that margin compression is transitory rather than structural. The average analyst target of $37.24 aligns with the base case range.
ROL appears overvalued on earnings-based metrics but fairly valued to slightly undervalued on sales-based metrics. The trailing PE of 55.06x and forward PE of 28.17x are well above the specialty business services sector average in the low-to-mid 20s, representing a premium of over 100% on trailing earnings. However, the PS ratio of 7.73x is near the low end of its historical 18x–32x range, suggesting the price decline has compressed the sales multiple dramatically. The PEG ratio of 4.07x indicates the stock is expensive relative to its growth rate, implying the market expects earnings to roughly double (forward EPS of $1.597 vs. trailing $0.018). Overall, the market is pricing in a recovery that has yet to materialize.
From a risk/reward perspective, ROL presents a mixed picture. The stock offers +6.9% upside to the average analyst target of $37.24, but downside to the 52-week low of $29.29 is -15.9%, and to the analyst low target of $26.00 is -25.3%. The valuation remains rich at 55.06x trailing PE and 28.17x forward PE, though the PS ratio of 7.73x is near the low end of its historical range. For long-term investors with a 3-5 year horizon, the recurring revenue model and strong FCF generation may justify gradual accumulation, but near-term momentum and margin trends argue for patience. It is a better buy if the stock stabilizes above $38–$40 or if forward PE compresses below 25x.
ROL is better suited for long-term investment given its defensive, recurring-revenue business model and low beta of 0.731. The company pays a modest dividend (yield 1.13%, payout ratio 62.3%), supporting a total-return approach for patient investors. However, the current technical downtrend and negative momentum (-38.69% over one year) make short-term trading risky, as the stock could test the $29.29 low. Earnings visibility is moderate, with analyst revenue estimates of $5.26 billion for the year. A suggested minimum holding period is 2-3 years to allow for margin stabilization and multiple normalization. Short-term traders should wait for confirmation of a trend reversal above $38–$40 before entering.